MGRN1 and Miyoshi myopathy: Overall, these results proved that a 4g signature combining MGRN1 and 3 MM biomarkers identified a subset of patients with favorable (0–IIIB) TNM stage but adverse outcomes (OS comparable with the median of patients with advanced IIIC–IV TNM stage).